Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,303 | 591 | 97.3% |
| Education | $288.09 | 10 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $1,974 | 102 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $1,372 | 59 | $0 (2023) |
| Alkermes, Inc. | $1,299 | 60 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $835.40 | 49 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $704.43 | 41 | $0 (2022) |
| Lundbeck LLC | $682.07 | 39 | $0 (2023) |
| Shire North American Group Inc | $425.78 | 33 | $0 (2019) |
| Neurocrine Biosciences, Inc. | $378.53 | 20 | $0 (2023) |
| Vanda Pharmaceuticals Inc. | $357.88 | 27 | $0 (2020) |
| Indivior Inc. | $307.42 | 23 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $75.70 | 4 | E.R. Squibb & Sons, L.L.C. ($44.02) |
| 2023 | $416.58 | 19 | Alkermes, Inc. ($109.82) |
| 2022 | $647.85 | 34 | Sunovion Pharmaceuticals Inc. ($344.00) |
| 2021 | $576.65 | 30 | Sunovion Pharmaceuticals Inc. ($301.44) |
| 2020 | $773.15 | 43 | Sunovion Pharmaceuticals Inc. ($187.23) |
| 2019 | $3,418 | 193 | Otsuka America Pharmaceutical, Inc. ($775.52) |
| 2018 | $2,381 | 141 | Sunovion Pharmaceuticals Inc. ($464.55) |
| 2017 | $2,302 | 137 | Alkermes, Inc. ($385.27) |
All Payment Transactions
601 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $16.75 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Education | In-kind items and services | $27.27 | General |
| Category: Psychiatry/Psychology | ||||||
| 08/19/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $8.15 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 01/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: NEUROSCIENCE | ||||||
| 12/14/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.06 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.54 | General |
| Category: Neuropsychiatry | ||||||
| 10/12/2023 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: ANTI-ANXIETY | ||||||
| 10/10/2023 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 09/07/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $26.56 | General |
| Category: CNS | ||||||
| 08/24/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: PSYCHIATRY | ||||||
| 08/15/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $23.49 | General |
| Category: PSYCHOLOGY | ||||||
| 07/19/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: Neuropsychiatry | ||||||
| 07/11/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: CNS | ||||||
| 06/22/2023 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $26.28 | General |
| Category: BH | ||||||
| 06/13/2023 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: Neurology | ||||||
| 06/05/2023 | Lundbeck LLC | ABILIFY MAINTENA (Drug) | Food and Beverage | Cash or cash equivalent | $33.59 | General |
| Category: PSYCHIATRY | ||||||
| 05/11/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: CNS | ||||||
| 05/08/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: Central Nervous System | ||||||
| 04/14/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: CNS | ||||||
| 04/10/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Central Nervous System | ||||||
| 03/14/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: CNS | ||||||
| 02/16/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: Central Nervous System | ||||||
| 01/23/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: Central Nervous System | ||||||
| 12/15/2022 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2022 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $8.15 | General |
| Category: Central Nervous System | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 147 | 304 | $127,466 | $27,166 |
| 2022 | 6 | 260 | 545 | $133,336 | $50,970 |
| 2021 | 5 | 316 | 727 | $171,462 | $74,663 |
| 2020 | 5 | 314 | 730 | $161,549 | $65,941 |
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 88 | 242 | $97,085 | $17,834 | 18.4% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 24 | 26 | $21,455 | $6,291 | 29.3% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2023 | 20 | 21 | $5,712 | $2,126 | 37.2% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 15 | 15 | $3,214 | $913.50 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 116 | 324 | $57,840 | $24,482 | 42.3% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 41 | 45 | $33,042 | $10,956 | 33.2% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 13 | 34 | $17,770 | $6,690 | 37.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 55 | 84 | $14,960 | $5,160 | 34.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 42 | $5,372 | $1,987 | 37.0% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2022 | 15 | 16 | $4,352 | $1,696 | 39.0% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 74 | 129 | $81,528 | $31,853 | 39.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 132 | 399 | $59,850 | $30,814 | 51.5% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 76 | 145 | $21,750 | $9,010 | 41.4% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2021 | 14 | 16 | $4,352 | $1,720 | 39.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 38 | $3,982 | $1,266 | 31.8% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 64 | 118 | $74,576 | $28,830 | 38.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 157 | 441 | $66,150 | $28,533 | 43.1% |
| 80307 | Testing for presence of drug | Office | 2020 | 63 | 115 | $17,250 | $7,072 | 41.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 26 | $2,673 | $775.34 | 29.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 16 | 30 | $900.00 | $730.80 | 81.2% |
About Dr. Hansen Su, MD
Dr. Hansen Su, MD is a Psychiatry healthcare provider based in Hillsborough, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952372591.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hansen Su, MD has received a total of $10,591 in payments from pharmaceutical and medical device companies, with $75.70 received in 2024. These payments were reported across 601 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($10,303).
As a Medicare-enrolled provider, Su has provided services to 1,037 Medicare beneficiaries, totaling 2,306 services with total Medicare billing of $218,740. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Location Hillsborough, NC
- Active Since 01/31/2006
- Last Updated 09/08/2016
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1952372591
Products in Payments
- LATUDA (Drug) $1,974
- REXULTI (Drug) $1,058
- ABILIFY MAINTENA (Drug) $722.77
- ARISTADA (Drug) $687.37
- Aristada 441 mg (Drug) $557.60
- AUSTEDO (Drug) $554.59
- INVEGA SUSTENNA (Drug) $446.15
- VRAYLAR (Drug) $429.59
- INGREZZA (Drug) $378.53
- Fanapt (Drug) $341.35
- VYVANSE (Drug) $292.05
- Trintellix (Drug) $272.73
- NUEDEXTA (Drug) $215.04
- MYDAYIS (Drug) $186.09
- SUBLOCADE (Drug) $178.14
- TRINTELLIX (Drug) $169.76
- Evekeo (Drug) $163.42
- Adzenys XR-ODT (Drug) $161.86
- INVEGA TRINZA (Drug) $155.68
- Dyanavel XR (Drug) $132.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Hillsborough
Brian Wall, Md, MD
Psychiatry — Payments: $9,574
Yuange Hu, M.d, M.D
Psychiatry — Payments: $1,387
Susan Blank, Md, MD
Psychiatry — Payments: $1,386
Kathleen Sisk, Pmh-Np, PMH-NP
Psychiatry — Payments: $1,242
Dr. Ali Zomorodi, Md, MD
Psychiatry — Payments: $346.58
Dr. Joseph Rochford, Md, MD
Psychiatry — Payments: $198.90